FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600140129> ?p ?o ?g. }

• W2600140129 abstract "e19045 Background: BV (Avastin), an anti-VEGF monoclonal antibody, prolongs progression-free and overall survival in advanced NSCLC pts. Severe (≥grade 3) pulmonary hemorrhage (sPH) is a rare but serious event that has been associated with BV-based therapy in phase 3 trials (rate of 2–4%). Potential risk factors include squamous histology, prior history of hemoptysis, and presence of tumor cavitation. Rates of baseline (BL) cavitation in NSCLC pts and development of cavitation on BV therapy are unknown. Pts in ARIES, an OCS of approximately 2,000 pts with NSCLC, had BL scans assessed for tumor cavitation. A substudy of approximately 250 pts also had follow-up scans to analyze the likelihood of developing cavitation on BV therapy. For the entire ARIES population, any pt developing sPH is assessed for tumor cavitation. Methods: Pts at specified ARIES sites submitted on-treatment CT scans to an independent review facility (IRF), in addition to BL scans. Evaluable pts had measurable disease at BL and at least one-post-BL scan. Correlations between cavitation (pre-existing or developing on-study) and clinical, tumor and treatment characteristics are evaluated using a chi-squared test or t-test. Incidence of sPH based on cavitation status will be assessed using Fisher's exact test. Results: As of 9/15/08, 210 pts had a post-BL CT scan reviewed by the IRF. Of these pts, 171 had measurable tumors at BL. For the 171 pt cohort: median F/U is 9.2 m; 99% have ≥1 quarterly update. Key BL characteristics for the substudy and overall cohorts, respectively, include: 44% vs 51% ≥65 yrs; 67% vs 67% adenocarcinoma; 6% vs 5% therapeutic AC. BL radiographic features: 41% vs 39% presence of central tumor; 13% vs 15% presence of cavitation. In substudy pts, there is 1 sPH to date in a pt without baseline cavitation. Conclusions: sPH is a rare, potentially serious event in pts with NSCLC receiving BV. Whether cavitation (BL or developing on-treatment) is associated with an increased risk of sPH has not been defined. The final analysis of an ARIES Lung substudy assessing on-study development of cavitation and association with sPH will be presented at the meeting. [Table: see text]" @default.
• W2600140129 created "2017-04-07" @default.
• W2600140129 creator A5000503166 @default.
• W2600140129 creator A5020334650 @default.
• W2600140129 creator A5035368609 @default.
• W2600140129 creator A5037796365 @default.
• W2600140129 creator A5058969820 @default.
• W2600140129 creator A5061588609 @default.
• W2600140129 creator A5064266725 @default.
• W2600140129 creator A5088998288 @default.
• W2600140129 date "2009-05-20" @default.
• W2600140129 modified "2023-10-16" @default.
• W2600140129 title "Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES—A bevacizumab (BV) treatment observational cohort study (OCS)" @default.
• W2600140129 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e19045" @default.
• W2600140129 hasPublicationYear "2009" @default.
• W2600140129 type Work @default.
• W2600140129 sameAs 2600140129 @default.
• W2600140129 citedByCount "0" @default.
• W2600140129 crossrefType "journal-article" @default.
• W2600140129 hasAuthorship W2600140129A5000503166 @default.
• W2600140129 hasAuthorship W2600140129A5020334650 @default.
• W2600140129 hasAuthorship W2600140129A5035368609 @default.
• W2600140129 hasAuthorship W2600140129A5037796365 @default.
• W2600140129 hasAuthorship W2600140129A5058969820 @default.
• W2600140129 hasAuthorship W2600140129A5061588609 @default.
• W2600140129 hasAuthorship W2600140129A5064266725 @default.
• W2600140129 hasAuthorship W2600140129A5088998288 @default.
• W2600140129 hasConcept C126322002 @default.
• W2600140129 hasConcept C143998085 @default.
• W2600140129 hasConcept C191093355 @default.
• W2600140129 hasConcept C2776256026 @default.
• W2600140129 hasConcept C2776694085 @default.
• W2600140129 hasConcept C2777802072 @default.
• W2600140129 hasConcept C2908647359 @default.
• W2600140129 hasConcept C2989005 @default.
• W2600140129 hasConcept C71924100 @default.
• W2600140129 hasConcept C72563966 @default.
• W2600140129 hasConcept C99454951 @default.
• W2600140129 hasConceptScore W2600140129C126322002 @default.
• W2600140129 hasConceptScore W2600140129C143998085 @default.
• W2600140129 hasConceptScore W2600140129C191093355 @default.
• W2600140129 hasConceptScore W2600140129C2776256026 @default.
• W2600140129 hasConceptScore W2600140129C2776694085 @default.
• W2600140129 hasConceptScore W2600140129C2777802072 @default.
• W2600140129 hasConceptScore W2600140129C2908647359 @default.
• W2600140129 hasConceptScore W2600140129C2989005 @default.
• W2600140129 hasConceptScore W2600140129C71924100 @default.
• W2600140129 hasConceptScore W2600140129C72563966 @default.
• W2600140129 hasConceptScore W2600140129C99454951 @default.
• W2600140129 hasLocation W26001401291 @default.
• W2600140129 hasOpenAccess W2600140129 @default.
• W2600140129 hasPrimaryLocation W26001401291 @default.
• W2600140129 hasRelatedWork W1967103478 @default.
• W2600140129 hasRelatedWork W2018889021 @default.
• W2600140129 hasRelatedWork W2032912323 @default.
• W2600140129 hasRelatedWork W2372561159 @default.
• W2600140129 hasRelatedWork W2385168578 @default.
• W2600140129 hasRelatedWork W2387455091 @default.
• W2600140129 hasRelatedWork W2390152934 @default.
• W2600140129 hasRelatedWork W2603773853 @default.
• W2600140129 hasRelatedWork W4238549103 @default.
• W2600140129 hasRelatedWork W4380186280 @default.
• W2600140129 isParatext "false" @default.
• W2600140129 isRetracted "false" @default.
• W2600140129 magId "2600140129" @default.
• W2600140129 workType "article" @default.